uniQure N.V. (QURE) Stock Posts 30% Growth from Last Year

On March 11, Mizuho Securities upgraded its terms people connected uniQure to $35 from $12. Similarly, RBC Capital besides upgraded its terms people connected uniQure to $35 from $11 connected March 9.

uniQure Chief Executive Officer Matt Kapusta earlier expressed the company’s committedness to engaging with the FDA regarding the support pathway for its AMT-130 for Huntington’s disease. He said:

“While we person not reached alignment with the FDA connected an support pathway, we stay assured successful the spot and durability reflected successful our dataset. We are committed to engaging with the FDA to specify a wide and businesslike way to bring this perchance transformative therapy to Huntington’s illness patients successful urgent request for treatments.”

Beyond Huntington’s disease, Kapusta said the institution has besides made meaningful advancement crossed its broader objective portfolio and looks guardant to further information readouts aboriginal this year.

uniQure N.V. (NASDAQ:QURE) is simply a starring cistron therapy institution advancing transformative therapies for patients with terrible aesculapian needs specified arsenic hemophilia B. The institution is present advancing a pipeline of proprietary cistron therapies for the attraction of patients with Huntington’s disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and different terrible diseases.

While we admit the imaginable of QURE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Data Center Stocks to Buy for the Long Term and 8 Must-Buy Small Cap Stocks to Buy.

Disclosure: None. Follow Insider Monkey connected Google News.